Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.

ABSTRACT: Inotuzumab ozogamicin (InO) is a recently US Food and Drug Administration-approved antibody-drug conjugate for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). InO consists of a CD22-targeting immunoglobulin G4 humanized monoclonal antibody conjugated to calicheamicin. Although initially developed for the treatment of non-Hodgkin lymphoma (NHL) because of activity in preclinical models and high response rates in indolent lymphomas, a phase 3 trial was negative and further development focused on CD22⁺ ALL. Although results in NHL were disappointing, parallel testing in early-phase trials of CD22⁺ ALL demonstrated feasibility and efficacy. Subsequently, the randomized phase 3 Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of C

SUBMITTER: Wynne J 

PROVIDER: S-EPMC6325303 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature